Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post Marketing Surveillance to Monitor the Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ When Administered According to the Prescribing Information to Indian Infants

NCT00938327 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00938327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00938327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post Marketing Surveillance to Monitor the Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ When Administered According to the Prescribing Information to Indian Infants
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
August 3, 2009
Completion date
April 23, 2010
Enrollment
332 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

infections, rotavirus